Respiratory failure & ventilation

Risk Stratification and Management of Acute Respiratory Failure in Patients With Neuromuscular Disease

Crit Care MedPublished Narrative review

Authors' conclusion

Multimodal assessments integrating several bedside indicators of bulbar and respiratory muscle function can aid in evidence-based risk stratification for respiratory failure among those with neuromuscular disease.

Study context

Population
Patients with acute neuromuscular respiratory failure due to Guillain-Barré syndrome (GBS) or myasthenia gravis (MG)
Outcome
Prediction and management of acute neuromuscular respiratory failure
Methodological detailssynthetic narrative review, PubMed search plus bibliographies of included articles; English-language publications; qualitative assessment
  • Synthetic narrative review
  • PubMed search plus bibliographies of included articles; English-language publications; qualitative assessment

Main finding

As reported in the abstract

  • No single tool has sufficient sensitivity and specificity to predict respiratory failure requiring mechanical ventilation
  • Multimodal assessment (history, single breath count, neck flexion strength, bulbar weakness, paradoxical breathing, pulmonary function testing) ideal for risk stratification
  • Erasmus GBS Respiratory Insufficiency Score is a validated tool useful for GBS
  • NIV can be effective in MG but may not be safe in early GBS
  • Airway management similar in both; dysautonomia in GBS requires specific attention
  • Extubation failure common in MG; early tracheostomy may be beneficial for MG
  • Prolonged ventilatory support common; good functional outcomes may occur even with prolonged ventilation

Original publication

Risk Stratification and Management of Acute Respiratory Failure in Patients With Neuromuscular Disease. Crit Care Med. Published 19 September 2024. doi:10.1097/ccm.0000000000006417

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.